Overview

Since its humble beginnings in October 2001, Celltrion Healthcare has become one of the world’s recognized players in the area of biosimilars, with operations in over 110 countries and more than 30 worldwide partners. Our goal is to provide effective and affordable therapeutics to patients everywhere. Our dream is to develop innovative new drugs and become a global biopharmaceutical leader. Now, with the opening of operations in Canada, this dream has become a reality for all Canadians who are in need. In January 2021, Celltrion Healthcare received Health Canada marketing authorization for world's first subcutaneous formulation of infliximab, RemsimaTM SC, for the treatment of people with rheumatoid arthritis. Rheumatoid arthritis is the most common chronic inflammatory joint disease, affecting approximately 374,000 Canadians over the age of 16. In December 2021, Celltrion Healthcare Canada received Health Canada marketing authorization for Yuflyma®, a high-concentration (100 mg/mL), low-volume, citrate-free, and latex-free biosimilar to Humira® (adalimumab). Yuflyma® is approved in ten indications for the treatment of multiple chronic inflammatory diseases, including rheumatoid arthritis, polyarticular juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, adult Crohn's disease, adult ulcerative colitis, hidradenitis suppurativa, plaque psoriasis, adult uveitis, and pediatric uveitis. We are proud to expand our biosimilar portfolio in Canada, with Remsima™ SC in 2021, and now with Yuflyma®, bringing innovative therapies to help patients on their treatment journey. We will be a contributor to the overall Celltrion journey to become a leading global biopharmaceutical company. At the same time, we will work tirelessly to bring effective therapies to Canadians from coast to coast.